nach oben

Erschienen in:

01.02.2016 | Women's Mental Health (CN Epperson, Section Editor)

Bipolar Disorder in Pregnancy and Postpartum: Principles of Management

verfasst von: Sabrina J. Khan, Madeleine E. Fersh, Carrie Ernst, Kim Klipstein, Elizabeth Streicker Albertini, Shari I. Lusskin

Erschienen in: Current Psychiatry Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Pregnancy and postpartum represent times of increased vulnerability for women with bipolar disorder, yet this condition remains under-diagnosed and under-treated. As 50 % of pregnancies are unplanned, the risks associated with the illness and the potential risks associated with treatment should be considered when a woman of reproductive age first presents for evaluation. This article reviews the epidemiology of perinatal bipolar disorder, screening recommendations, and treatment with pharmacotherapy and electroconvulsive therapy (ECT). An overview of the data in pregnancy and lactation is presented for lithium, lamotrigine, valproic acid, newer antipsychotics, and ECT. General principles of management include close monitoring in pregnancy and postpartum, careful adjustment of the treatment regimen to attenuate the risk of relapse, and avoidance of valproic acid when possible. Thoughtful consideration of these issues will minimize the risks to the mother and baby.

Jones I, Chandra PS, Dazzan P, Howard LM. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet. 2014;384(9956):1789–99. doi:10.1016/s0140-6736(14)61278-2.CrossRefPubMed

Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63(4):284–7.CrossRefPubMed

Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24. doi:10.1176/appi.ajp.2007.06101639.CrossRefPubMed

Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum depression: detection, diagnosis, and treatment. Am J Psychiatry. 2009;166(11):1217–21. doi:10.1176/appi.ajp.2009.08121902.CrossRefPubMed

Frey BN, Simpson W, Wright L, Steiner M. Sensitivity and specificity of the Mood Disorder Questionnaire as a screening tool for bipolar disorder during pregnancy and the postpartum period. J Clin Psychiatry. 2012;73(11):1456–61. doi:10.4088/JCP.12m07856.CrossRefPubMed

Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118 Suppl 1:1–203. doi:10.1111/j.1471-0528.2010.02847.x.PubMed

Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry. 2000;157(2):179–84.CrossRefPubMed

Bergink V, Armangue T, Titulaer MJ, Markx S, Dalmau J, Kushner SA. Autoimmune encephalitis in postpartum psychosis. Am J Psychiatry. 2015:appiajp201514101332. doi:10.1176/appi.ajp.2015.14101332.

Merrill L, Mittal L, Nicoloro J, Caiozzo C, Maciejewski PK, Miller LJ. Screening for bipolar disorder during pregnancy. Arch Womens Ment Health. 2015;18(4):579–83. doi:10.1007/s00737-015-0527-y.CrossRefPubMed

10.

Chessick CA, Dimidjian S. Screening for bipolar disorder during pregnancy and the postpartum period. Arch Womens Ment Health. 2010;13(3):233–48. doi:10.1007/s00737-010-0151-9.CrossRefPubMed

11.

Sharma V, Xie B. Screening for postpartum bipolar disorder: validation of the Mood Disorder Questionnaire. J Affect Disord. 2011;131(1–3):408–11. doi:10.1016/j.jad.2010.11.026.CrossRefPubMed

12.

Sharma V, Pope CJ. Pregnancy and bipolar disorder: a systematic review. J Clin Psychiatry. 2012;73(11):1447–55. doi:10.4088/JCP.11r07499.CrossRefPubMed

13.

March of Dimes Foundation. Quick facts: birth defects. 2013 [8/5/15]; Available from: http://www.marchofdimes.com/peristats/ViewTopic.aspx?reg=99&top=16&lev=0&slev=1&dv=mt.

14.

Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345, e7085. doi:10.1136/bmj.e7085.PubMedCentralCrossRefPubMed

15.

Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004;161(4):608–20.CrossRefPubMed

16.

Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatr. 2005;162(11):2162–70.CrossRefPubMed

17.

Nora JJ, Nora AH, Toews WH. Letter: Lithium, Ebstein’s anomaly, and other congenital heart defects. Lancet. 1974;2(7880):594–5.CrossRefPubMed

18.

Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium.[see comment][erratum appears in JAMA 1994 May 18;271(19):1485]. JAMA. 1994;271(2):146–50.

19.••

Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171(7):785–94. doi:10.1176/appi.ajp.2014.12111402. This is a prospective, comparative observational study evaluating the risk of major malformations associated with lithium exposure during pregnancy. Lithium exposure was associated with an increased rate of cardiovascular anomalies (5/123 [4.1%] compared with 4/711 [0.6%] in the non-teratogenic exposure group), however this risk was no longer statistically significant after excluding malformations which resolved spontaneously. CrossRefPubMed

20.

Kozma C. Neonatal toxicity and transient neurodevelopmental deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Am J Med Genet A. 2005;132A(4):441–4. doi:10.1002/ajmg.a.30501.CrossRefPubMed

21.•

van der Lugt NM, van de Maat JS, van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ. Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies. Early Hum Dev. 2012;88(6):375–8. doi:10.1016/j.earlhumdev.2011.09.013. This observational retrospective cohort study evaluated the growth and neurodevelopment of 15 children exposed to lithium in pregnancy at 3–15 years and found that lithium exposure was not associated with adverse effects on growth and cognitive development. CrossRefPubMed

22.••

Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014;34(2):244–55. doi:10.1097/jcp.0000000000000087. This paper reviews the pharmacokinetic changes of antidepressants and mood stabilizers during pregnancy, discusses the implications for clinical and therapeutic drug monitoring, and offers clinical recommendations. PubMedCentralCrossRefPubMed

23.

Bergink V, Kushner SA. Lithium during pregnancy. Am J Psychiatry. 2014;171(7):712–5. doi:10.1176/appi.ajp.2014.14030409.CrossRefPubMed

24.

Viguera AC, Newport D, Ritchie J, Stowe Z, Whitfield T, Mogielnicki J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry. 2007;164(2):342–5.CrossRefPubMed

25.

Marin Gabriel MA, Olza Fernandez I, Donoso E, Gutierrez Cruz N. Lithium and artificial breastmilk; or is maternal breastfeeding better? An Pediatr (Barc). 2011;75(1):67–8. doi:10.1016/j.anpedi.2010.12.007.CrossRef

26.

Bogen DL, Sit D, Genovese A, Wisner KL. Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health. 2012;15(1):69–72. doi:10.1007/s00737-012-0257-3.PubMedCentralCrossRefPubMed

27.

Tomson T, Battino D. Antiepileptic treatment in pregnant women: morphological and behavioural effects. Handb Exp Pharmacol. 2011;205:295–315. doi:10.1007/978-3-642-20195-0_15.CrossRefPubMed

28.

Werler MM, Ahrens KA, Bosco JL, Mitchell AA, Anderka MT, Gilboa SM, et al. Use of antiepileptic medications in pregnancy in relation to risks of birth defects. Ann Epidemiol. 2011;21(11):842–50. doi:10.1016/j.annepidem.2011.08.002.CrossRefPubMed

29.

Mawhinney E, Campbell J, Craig J, Russell A, Smithson W, Parsons L, et al. Valproate and the risk for congenital malformations: is formulation and dosage regime important? Seizure. 2012;21(3):215–8. doi:10.1016/j.seizure.2012.01.005.CrossRefPubMed

30.

Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC, Group NS. In utero antiepileptic drug exposure: fetal death and malformations.[see comment]. Neurology. 2006;67(3):407–12.

31.

Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78(21):1692–9. doi:10.1212/WNL.0b013e3182574f39.CrossRefPubMed

32.

Diav-Citrin O, Shechtman S, Bar-Oz B, Cantrell D, Arnon J, Ornoy A. Pregnancy outcome after in utero exposure to valproate: evidence of dose relationship in teratogenic effect. CNS Drugs. 2008;22(4):325–34.CrossRefPubMed

33.

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–17. doi:10.1016/S1474-4422(11)70107-7.CrossRefPubMed

34.

Vajda FJ, O'Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal malformations associated with valproate. Neurology. 2013;81(11):999–1003. doi:10.1212/WNL.0b013e3182a43e81.CrossRefPubMed

35.

Ozkan H, Cetinkaya M, Koksal N, Yapici S. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med. 2011;24(3):521–4. doi:10.3109/14767058.2010.501120.CrossRefPubMed

36.•

Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–703. doi:10.1001/jama.2013.2270. This Danish population based study found that prenatal exposure to valproate was associated with an increased risk of autism spectrum disorder and childhood autism; the 508 children exposed to valproate had an absolute risk of 4.42 % (95 % CI, 2.59–7.46 %) for autism spectrum disorder (adjusted HR, 2.9 [95 % CI, 1.7–4.9]) and an absolute risk of 2.50 % (95 % CI, 1.30–4.81 %) for childhood autism (adjusted HR, 5.2 [95 % CI, 2.7–10.0]).PubMedCentralCrossRefPubMed

37.

FDA. Valproate sodium and related products (valproic acid and divalproex sodium): risk of birth defects: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm192788.htm [released 12/3/09]. 2009 [8/14/15].

38.

Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22.CrossRefPubMed

39.

Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305(19):1996–2002. doi:10.1001/jama.2011.624.CrossRefPubMed

40.

Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–34. doi:10.1136/jnnp-2013-306318.CrossRefPubMed

41.

Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579–88. doi:10.1007/s00415-013-7239-x.CrossRefPubMed

42.

Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–52. doi:10.1016/s1474-4422(12)70323-x.PubMedCentralCrossRefPubMed

43.

Baker GA, Bromley RL, Briggs M, Cheyne CP, Cohen MJ, Garcia-Finana M, et al. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84(4):382–90. doi:10.1212/wnl.0000000000001182.PubMedCentralCrossRefPubMed

44.

Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10, Cd010236. doi:10.1002/14651858.CD010236.pub2.PubMed

45.

Veiby G, Daltveit AK, Schjolberg S, Stoltenberg C, Oyen AS, Vollset SE, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013;54(8):1462–72. doi:10.1111/epi.12226.PubMedCentralCrossRefPubMed

46.•

Paulzen M, Lammertz SE, Veselinovic T, Goecke TW, Hiemke C, Grunder G. Lamotrigine in pregnancy—therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol. 2015;30(5):249–54. doi:10.1097/yic.0000000000000088. This study measured lamotrigine concentrations in maternal blood, amniotic fluid, and umbilical cord blood in six mother-infant pairs at delivery. Lamotrigine levels in serum were strongly correlated with the lamotrigine levels in the amniotic fluid and cord blood. PubMed

47.

Kacirova I, Grundmann M, Brozmanova H. Serum levels of lamotrigine during delivery in mothers and their infants. Epilepsy Res. 2010;91(2–3):161–5. doi:10.1016/j.eplepsyres.2010.07.007.CrossRefPubMed

48.

Fotopoulou C, Kretz R, Bauer S, Schefold JC, Schmitz B, Dudenhausen J, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res. 2009;85(1):60–4.CrossRefPubMed

49.

Harden CL, Pennell PB, Koppel BS, Hovinga CA, Gidal B, Meador KJ, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):142–9. doi:10.1212/WNL.0b013e3181a6b325.PubMedCentralCrossRefPubMed

50.

Newport DJ, Stowe ZN, Viguera AC, Calamaras MR, Juric S, Knight B, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord. 2008;10(3):432–6. doi:10.1111/j.1399-5618.2007.00565.x.CrossRefPubMed

51.

Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry. 2013;170(11):1240–7. doi:10.1176/appi.ajp.2013.13010006.PubMedCentralCrossRefPubMed

52.

Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41(6):709–13.CrossRefPubMed

53.

Page-Sharp M, Kristensen JH, Hackett LP, Beran RG, Rampono J, Hale TW, et al. Transfer of lamotrigine into breast milk. Ann Pharmacother. 2006;40(7–8):1470–1.CrossRefPubMed

54.

Wakil L, Epperson CN, Gonzalez J, O'Reardon JP, Kim DR. Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. Psychopharmacol Bull. 2009;42(3):91–8.PubMed

55.

Veiby G, Engelsen BA, Gilhus NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013;70(11):1367–74. doi:10.1001/jamaneurol.2013.4290.CrossRefPubMed

56.

Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology. 2010;75(22):1954–60. doi:10.1212/WNL.0b013e3181ffe4a9.PubMedCentralCrossRefPubMed

57.

Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168(8):729–36. doi:10.1001/jamapediatrics.2014.118.PubMedCentralCrossRefPubMed

58.

Veiby G, Bjork M, Engelsen BA, Gilhus NE. Epilepsy and recommendations for breastfeeding. Seizure. 2015;28:57–65. doi:10.1016/j.seizure.2015.02.013.CrossRefPubMed

59.

Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47(1–2):151–4.CrossRefPubMed

60.

Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61(4):570–1.CrossRefPubMed

61.

Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48(3):484–9. doi:10.1111/j.1528-1167.2007.00997.x.CrossRefPubMed

62.

Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG. Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ. 2015;350:h2298. doi:10.1136/bmj.h2298.PubMedCentralCrossRefPubMed

63.

McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study.[see comment]. Journal of Clinical Psychiatry. 2005;66(4):444–9; quiz 546.

64.

Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279–88. doi:10.1097/JCP.0b013e318172b8d5.CrossRefPubMed

65.

Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–62. doi:10.1097/JCP.0b013e318295fe12.CrossRefPubMed

66.

Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5), e94788. doi:10.1371/journal.pone.0094788.PubMedCentralCrossRefPubMed

67.••

Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. Basic Clin Pharmacol Toxicol. 2014. doi:10.1111/bcpt.12372. A literature review of the available data on the risk of malformations with first-trimester exposure to the newer antipsychotics: olanzapine, quetiapine, risperidone and aripiprazole. The rate of malformation was 3.5 % for olanzapine, 3.6 % with quetiapine, and 5.1 % with risperidone; data for aripiprazole was limited.

68.

Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015;125(5):1224–35. doi:10.1097/aog.0000000000000759.CrossRefPubMed

69.

Boden R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715–21. doi:10.1001/archgenpsychiatry.2011.1870.CrossRefPubMed

70.

Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol. 2015;35(5):559–65. doi:10.1097/JCP.0000000000000391.CrossRefPubMed

71.

FDA. FDA Drug Safety Communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm [released 2/22/2011]. 2011 [8/14/15].

72.

Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69(8):787–94. doi:10.1001/archgenpsychiatry.2012.160.PubMedCentralCrossRefPubMed

73.

Peng M, Gao K, Ding Y, Ou J, Calabrese JR, Wu R, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berlin). 2013. doi:10.1007/s00213-013-3060-6.

74.

Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164(8):1214–20.CrossRefPubMed

75.

Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009;114(3):703–13. doi:10.1097/AOG.0b013e3181ba0632.PubMedCentralCrossRefPubMed

76.

Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Commun Psychiatry. 1994;45(May):444–50.

77.

Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med. 2009;71(2):235–42. doi:10.1097/PSY.0b013e318190d7ca.CrossRefPubMed

78.

Leiknes KA, Cooke MJ, Jarosch-von Schweder L, Harboe I, Hoie B. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Womens Ment Health. 2015;18(1):1–39. doi:10.1007/s00737-013-0389-0.PubMedCentralCrossRefPubMed

Titel: Bipolar Disorder in Pregnancy and Postpartum: Principles of Management
verfasst von: Sabrina J. Khan
Madeleine E. Fersh
Carrie Ernst
Kim Klipstein
Elizabeth Streicker Albertini
Shari I. Lusskin
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 2/2016
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-015-0658-x

Neu im Fachgebiet Psychiatrie

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Interventions for the Carers of Patients With Eating Disorders

Identification and Management of Chronic Pain in Primary Care: a Review

Literature Review of Cognitive Neuroscience and Anorexia Nervosa

Prevention of Post-Traumatic Stress Disorder After Trauma: Current Evidence and Future Directions